The publisher has released a research report titled “Global Gastric Cancer Market (2024 Edition)” which provides a Gastric Cancer/Gastroesophageal Junction Cancer analysis of the Global Gastric Cancer industry in terms of market segmentation By Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumors), By Therapy (Immunotherapy, Chemotherapy, and Radiation Therapy and Surgery, Target Therapies) By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists VEGFR2 Antagonists, Other Drug Classes) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.
The Global Gastric Cancer market showcased growth at a CAGR of 10.27% during 2020-2023. The market was valued at USD 6.73 Billion in 2023 which is expected to reach USD 14.48 Billion in 2030.
Gastric cancer ranks as the third leading cause of cancer-related deaths globally, according to the World Health Organization. Annually, approximately 1 million new cases are diagnosed, and over 766,000 deaths occur worldwide. The prevalence and mortality rates of gastric cancer vary significantly across regions, with Eastern Asia experiencing the highest rates, followed by Eastern Europe and Central Asia. In contrast, North America, Western Europe, and Australasia report the lowest rates.
The aging population is a key risk factor for gastric cancer. As individuals age, the stomach lining becomes more vulnerable to changes that can lead to cancer. Additionally, older adults are more likely to suffer from chronic conditions such as atrophic gastritis, which causes the stomach lining to thin and become inflamed. The increasing elderly population in developed countries and rising life expectancy globally are significant drivers of the gastric cancer market.
Moreover, rising public awareness, advancements in diagnostics and treatments (including minimally invasive surgery and targeted therapies), and economic growth in some regions are further propelling market expansion.
The Global Gastric Cancer market showcased growth at a CAGR of 10.27% during 2020-2023. The market was valued at USD 6.73 Billion in 2023 which is expected to reach USD 14.48 Billion in 2030.
Gastric cancer ranks as the third leading cause of cancer-related deaths globally, according to the World Health Organization. Annually, approximately 1 million new cases are diagnosed, and over 766,000 deaths occur worldwide. The prevalence and mortality rates of gastric cancer vary significantly across regions, with Eastern Asia experiencing the highest rates, followed by Eastern Europe and Central Asia. In contrast, North America, Western Europe, and Australasia report the lowest rates.
The aging population is a key risk factor for gastric cancer. As individuals age, the stomach lining becomes more vulnerable to changes that can lead to cancer. Additionally, older adults are more likely to suffer from chronic conditions such as atrophic gastritis, which causes the stomach lining to thin and become inflamed. The increasing elderly population in developed countries and rising life expectancy globally are significant drivers of the gastric cancer market.
Moreover, rising public awareness, advancements in diagnostics and treatments (including minimally invasive surgery and targeted therapies), and economic growth in some regions are further propelling market expansion.
Scope of the Report
- The report analyses the Gastric Cancer Market by Value ( USD Billion).
- The report analyses the Gastric Cancer Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
- The report presents the analysis of Gastric Cancer Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
- The report analyses the Gastric Cancer Market By Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumors)
- The report analyses the Gastric Cancer Market By Therapy (Immunotherapy, Chemotherapy, and Radiation Therapy and Surgery, and Target Therapies).
- The report analyses the Gastric Cancer Market By Drug Class (PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Other Drug Classes).
- The key insights of the report have been presented through the frameworks of SWOT and Porter’s Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Indication, By Therapy and By Drug Class.
- Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
- The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Novartis, Pfizer, GSK plc., Bayer AG, Merck & Co., Inc., F. Hoffmann-La Roche AG, Eli Lily & Co., Celltrion Inc, Samsungbioepis Co,. Ltd, and Bristol Myers Squibb.
Table of Contents
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
1.2 Executive Summary
1.3 Research Methodology
2. Analyst Recommendations
2.1 Patient Education and Awareness Programs
2.2 Affordable Treatment Options
2.2 Affordable Treatment Options
3. Global Gastric Cancer Market: Historic and Forecast
3.1 Impact Analysis of Macro Economic Factors on Gastric Cancer Market
3.2 Gastric Cancer: Fact Sheet
3.3 Five-year Gastric Cancer survival rates
3.4 Prevalence of Gastric Cancer
3.5 Incidence of Gastric Cancer
3.6 Global Gastric Cancer Market: Dashboard
3.7 Global Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
3.8 Global Gastric Cancer Market: Market Value Assessment
3.9 Assessment Degree of Impact of COVID-19 on Global Gastric Cancer Market
3.10 Global Gastric Cancer Market Segmentation: By Indication
3.10.1 Global Gastric Cancer Market, By Indication Overview
3.10.2 Global Gastric Cancer Market Attractiveness Index, By Indication
3.10.3 Global Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
3.10.4 Global Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
3.11 Global Gastric Cancer Market Segmentation: By Therapy
3.11.1 Global Gastric Cancer Market, By Therapy Overview
3.11.2 Global Gastric Cancer Market Attractiveness Index, By Therapy
3.11.3 Global Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
3.11.4 Global Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
3.11.5 Global Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
3.11.6 Global Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
3.12 Global Gastric Cancer Market Segmentation: By Drug Class
3.12.1 Global Gastric Cancer Market, By Drug Class Overview
3.12.2 Global Gastric Cancer Market Attractiveness Index, By Drug Class
3.12.3 Global Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
3.12.4 Global Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
3.12.5 Global Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
3.12.6 Global Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
3.2 Gastric Cancer: Fact Sheet
3.3 Five-year Gastric Cancer survival rates
3.4 Prevalence of Gastric Cancer
3.5 Incidence of Gastric Cancer
3.6 Global Gastric Cancer Market: Dashboard
3.7 Global Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
3.8 Global Gastric Cancer Market: Market Value Assessment
3.9 Assessment Degree of Impact of COVID-19 on Global Gastric Cancer Market
3.10 Global Gastric Cancer Market Segmentation: By Indication
3.10.1 Global Gastric Cancer Market, By Indication Overview
3.10.2 Global Gastric Cancer Market Attractiveness Index, By Indication
3.10.3 Global Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
3.10.4 Global Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
3.11 Global Gastric Cancer Market Segmentation: By Therapy
3.11.1 Global Gastric Cancer Market, By Therapy Overview
3.11.2 Global Gastric Cancer Market Attractiveness Index, By Therapy
3.11.3 Global Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
3.11.4 Global Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
3.11.5 Global Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
3.11.6 Global Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
3.12 Global Gastric Cancer Market Segmentation: By Drug Class
3.12.1 Global Gastric Cancer Market, By Drug Class Overview
3.12.2 Global Gastric Cancer Market Attractiveness Index, By Drug Class
3.12.3 Global Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
3.12.4 Global Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
3.12.5 Global Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
3.12.6 Global Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
4. Gastric Cancer Market, Region Analysis
4.1 Regional Coverage of the Study
4.2 Regional Snapshot
4.2 Regional Snapshot
5. Americas Gastric Cancer Market: Historic and Forecast
5.1 Americas Gastric Cancer Market: Snapshot
5.2 Americas Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.3 Americas Gastric Cancer Market: Key Factors
5.4 Americas Gastric Cancer Market: Segment Analysis
5.5 Americas Gastric Cancer Market Segmentation: By Indication
5.5.1 Americas Gastric Cancer Market, By Indication Overview
5.5.2 Americas Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
5.5.3 Americas Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
5.6 Americas Gastric Cancer Market Segmentation: Therapy
5.6.1 Americas Gastric Cancer Market, By Therapy Overview
5.6.2 Americas Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
5.6.3 Americas Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
5.6.4 Americas Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
5.6.5 Americas Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
5.7 Americas Gastric Cancer Market Segmentation: By Drug Class
5.7.1 Americas Gastric Cancer Market, By Drug Class Overview
5.7.2 Americas Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
5.7.3 Americas Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
5.7.4 Americas Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
5.7.5 Americas Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
5.8 Americas Gastric Cancer Market Segmentation: By Country
5.8.1 Americas Gastric Cancer Market, by Country Overview
5.8.2 United States Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.8.2.1 United States Gastric Cancer Market, By Indication
5.8.2.2 United States Gastric Cancer Market, By Therapy
5.8.2.3 United States Gastric Cancer Market, By Drug Class
5.8.3 Canada Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.8.3.1 Canada Gastric Cancer Market, By Indication
5.8.3.2 Canada Gastric Cancer Market, By Therapy
5.8.3.3 Canada Gastric Cancer Market, By Drug Class
5.8.4 Rest of Americas Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.8.4.1 Rest of Americas Gastric Cancer Market, By Indication
5.8.4.2 Rest of Americas Gastric Cancer Market, By Therapy
5.8.4.3 Rest of Americas Gastric Cancer Market, By Drug Class
5.2 Americas Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.3 Americas Gastric Cancer Market: Key Factors
5.4 Americas Gastric Cancer Market: Segment Analysis
5.5 Americas Gastric Cancer Market Segmentation: By Indication
5.5.1 Americas Gastric Cancer Market, By Indication Overview
5.5.2 Americas Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
5.5.3 Americas Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
5.6 Americas Gastric Cancer Market Segmentation: Therapy
5.6.1 Americas Gastric Cancer Market, By Therapy Overview
5.6.2 Americas Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
5.6.3 Americas Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
5.6.4 Americas Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
5.6.5 Americas Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
5.7 Americas Gastric Cancer Market Segmentation: By Drug Class
5.7.1 Americas Gastric Cancer Market, By Drug Class Overview
5.7.2 Americas Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
5.7.3 Americas Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
5.7.4 Americas Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
5.7.5 Americas Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
5.8 Americas Gastric Cancer Market Segmentation: By Country
5.8.1 Americas Gastric Cancer Market, by Country Overview
5.8.2 United States Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.8.2.1 United States Gastric Cancer Market, By Indication
5.8.2.2 United States Gastric Cancer Market, By Therapy
5.8.2.3 United States Gastric Cancer Market, By Drug Class
5.8.3 Canada Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.8.3.1 Canada Gastric Cancer Market, By Indication
5.8.3.2 Canada Gastric Cancer Market, By Therapy
5.8.3.3 Canada Gastric Cancer Market, By Drug Class
5.8.4 Rest of Americas Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
5.8.4.1 Rest of Americas Gastric Cancer Market, By Indication
5.8.4.2 Rest of Americas Gastric Cancer Market, By Therapy
5.8.4.3 Rest of Americas Gastric Cancer Market, By Drug Class
6. Europe Gastric Cancer Market: Historic and Forecast
6.1 Europe Gastric Cancer Market: Snapshot
6.2 Europe Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.3 Europe Gastric Cancer Market: Key Factors
6.4 Europe Gastric Cancer Market: Segment Analysis
6.5 Europe Gastric Cancer Market Segmentation: By Indication
6.5.1 Europe Gastric Cancer Market, By Indication Overview
6.5.2 Europe Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
6.5.3 Europe Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
6.6 Europe Gastric Cancer Market Segmentation: By Therapy
6.6.1 Europe Gastric Cancer Market, By Therapy Overview
6.6.2 Europe Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
6.6.3 Europe Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
6.6.3 Europe Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
6.6.4 Europe Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
6.7 Europe Gastric Cancer Market Segmentation: By Drug Class
6.7.1 Europe Gastric Cancer Market, By Drug Class Overview
6.7.2 Europe Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
6.7.3 Europe Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
6.7.4 Europe Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
6.7.5 Europe Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
6.8 Europe Gastric Cancer Market Segmentation: By Country
6.8.1 Europe Gastric Cancer Market, by Country Overview
6.8.2 Germany Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.2.1 Germany Gastric Cancer Market, By Indication
6.8.2.2 Germany Gastric Cancer Market, By Therapy
6.8.2.3 Germany Gastric Cancer Market, By Drug Class
6.8.3 United Kingdom Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.3.1 United Kingdom Gastric Cancer Market, By Indication
6.8.3.2 United Kingdom Gastric Cancer Market, By Therapy
6.8.3.3 United Kingdom Gastric Cancer Market, By Drug Class
6.8.4 France Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.4.1 France Gastric Cancer Market, By Indication
6.8.4.2 France Gastric Cancer Market, By Therapy
6.8.4.3 France Gastric Cancer Market, By Drug Class
6.8.5 Italy Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.5.1 Italy Gastric Cancer Market, By Indication
6.8.5.2 Italy Gastric Cancer Market, By Therapy
6.8.5.3 Italy Gastric Cancer Market, By Drug Class
6.8.6 Spain Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.6.1 Spain Gastric Cancer Market, By Indication
6.8.6.2 Spain Gastric Cancer Market, By Therapy
6.8.6.3 Spain Gastric Cancer Market, By Drug Class
6.8.7 Rest of Europe Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.7.1 Rest of Europe Gastric Cancer Market, By Indication
6.8.7.2 Rest of Europe Gastric Cancer Market, By Therapy
6.8.7.3 Rest of Europe Gastric Cancer Market, By Drug Class
6.2 Europe Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.3 Europe Gastric Cancer Market: Key Factors
6.4 Europe Gastric Cancer Market: Segment Analysis
6.5 Europe Gastric Cancer Market Segmentation: By Indication
6.5.1 Europe Gastric Cancer Market, By Indication Overview
6.5.2 Europe Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
6.5.3 Europe Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
6.6 Europe Gastric Cancer Market Segmentation: By Therapy
6.6.1 Europe Gastric Cancer Market, By Therapy Overview
6.6.2 Europe Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
6.6.3 Europe Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
6.6.3 Europe Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
6.6.4 Europe Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
6.7 Europe Gastric Cancer Market Segmentation: By Drug Class
6.7.1 Europe Gastric Cancer Market, By Drug Class Overview
6.7.2 Europe Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
6.7.3 Europe Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
6.7.4 Europe Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
6.7.5 Europe Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
6.8 Europe Gastric Cancer Market Segmentation: By Country
6.8.1 Europe Gastric Cancer Market, by Country Overview
6.8.2 Germany Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.2.1 Germany Gastric Cancer Market, By Indication
6.8.2.2 Germany Gastric Cancer Market, By Therapy
6.8.2.3 Germany Gastric Cancer Market, By Drug Class
6.8.3 United Kingdom Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.3.1 United Kingdom Gastric Cancer Market, By Indication
6.8.3.2 United Kingdom Gastric Cancer Market, By Therapy
6.8.3.3 United Kingdom Gastric Cancer Market, By Drug Class
6.8.4 France Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.4.1 France Gastric Cancer Market, By Indication
6.8.4.2 France Gastric Cancer Market, By Therapy
6.8.4.3 France Gastric Cancer Market, By Drug Class
6.8.5 Italy Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.5.1 Italy Gastric Cancer Market, By Indication
6.8.5.2 Italy Gastric Cancer Market, By Therapy
6.8.5.3 Italy Gastric Cancer Market, By Drug Class
6.8.6 Spain Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.6.1 Spain Gastric Cancer Market, By Indication
6.8.6.2 Spain Gastric Cancer Market, By Therapy
6.8.6.3 Spain Gastric Cancer Market, By Drug Class
6.8.7 Rest of Europe Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
6.8.7.1 Rest of Europe Gastric Cancer Market, By Indication
6.8.7.2 Rest of Europe Gastric Cancer Market, By Therapy
6.8.7.3 Rest of Europe Gastric Cancer Market, By Drug Class
7. Asia Pacific Gastric Cancer Market: Historic and Forecast
7.1 Asia Pacific Gastric Cancer Market: Snapshot
7.2 Asia Pacific Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.3 Asia Pacific Gastric Cancer Market: Key Factors
7.4 Asia Pacific Gastric Cancer Market: Segment Analysis
7.5 Asia Pacific Gastric Cancer Market Segmentation: By Indication
7.5.1 Asia Pacific Gastric Cancer Market, By Indication Overview
7.5.2 Asia Pacific Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
7.5.3 Asia Pacific Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
7.6 Asia Pacific Gastric Cancer Market Segmentation: By Therapy
7.6.1 Asia Pacific Gastric Cancer Market, By Therapy Overview
7.6.2 Asia Pacific Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
7.6.3 Asia Pacific Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
7.6.3 Asia Pacific Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
7.6.4 Asia Pacific Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
7.7 Asia Pacific Gastric Cancer Market Segmentation: By Drug Class
7.7.1 Asia Pacific Gastric Cancer Market, By Drug Class Overview
7.7.2 Asia Pacific Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
7.7.3 Asia Pacific Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
7.7.4 Asia Pacific Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
7.7.5 Asia Pacific Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
7.8 Asia Pacific Gastric Cancer Market Segmentation: By Country
7.8.1 Asia Pacific Gastric Cancer Market, by Country Overview
7.8.2 China Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.2.1 China Gastric Cancer Market, By Indication
7.8.2.2 China Gastric Cancer Market, By Therapy
7.8.2.3 China Gastric Cancer Market, By Drug Class
7.8.3 Japan Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.3.1 Japan Gastric Cancer Market, By Indication
7.8.3.2 Japan Gastric Cancer Market, By Therapy
7.8.3.3 Japan Gastric Cancer Market, By Drug Class
7.8.4 India Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.4.1 India Gastric Cancer Market, By Indication
7.8.4.2 India Gastric Cancer Market, By Therapy
7.8.4.3 India Gastric Cancer Market, By Drug Class
7.8.5 Rest of Asia Pacific Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.5.1 Rest of Asia Pacific Gastric Cancer Market, By Indication
7.8.5.2 Rest of Asia Pacific Gastric Cancer Market, By Therapy
7.8.5.3 Rest of Asia Pacific Gastric Cancer Market, By Drug Class
7.2 Asia Pacific Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.3 Asia Pacific Gastric Cancer Market: Key Factors
7.4 Asia Pacific Gastric Cancer Market: Segment Analysis
7.5 Asia Pacific Gastric Cancer Market Segmentation: By Indication
7.5.1 Asia Pacific Gastric Cancer Market, By Indication Overview
7.5.2 Asia Pacific Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
7.5.3 Asia Pacific Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
7.6 Asia Pacific Gastric Cancer Market Segmentation: By Therapy
7.6.1 Asia Pacific Gastric Cancer Market, By Therapy Overview
7.6.2 Asia Pacific Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
7.6.3 Asia Pacific Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
7.6.3 Asia Pacific Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
7.6.4 Asia Pacific Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
7.7 Asia Pacific Gastric Cancer Market Segmentation: By Drug Class
7.7.1 Asia Pacific Gastric Cancer Market, By Drug Class Overview
7.7.2 Asia Pacific Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
7.7.3 Asia Pacific Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
7.7.4 Asia Pacific Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
7.7.5 Asia Pacific Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
7.8 Asia Pacific Gastric Cancer Market Segmentation: By Country
7.8.1 Asia Pacific Gastric Cancer Market, by Country Overview
7.8.2 China Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.2.1 China Gastric Cancer Market, By Indication
7.8.2.2 China Gastric Cancer Market, By Therapy
7.8.2.3 China Gastric Cancer Market, By Drug Class
7.8.3 Japan Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.3.1 Japan Gastric Cancer Market, By Indication
7.8.3.2 Japan Gastric Cancer Market, By Therapy
7.8.3.3 Japan Gastric Cancer Market, By Drug Class
7.8.4 India Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.4.1 India Gastric Cancer Market, By Indication
7.8.4.2 India Gastric Cancer Market, By Therapy
7.8.4.3 India Gastric Cancer Market, By Drug Class
7.8.5 Rest of Asia Pacific Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
7.8.5.1 Rest of Asia Pacific Gastric Cancer Market, By Indication
7.8.5.2 Rest of Asia Pacific Gastric Cancer Market, By Therapy
7.8.5.3 Rest of Asia Pacific Gastric Cancer Market, By Drug Class
8. Middle East and Africa Gastric Cancer Market: Historic and Forecast
8.1 Middle East and Africa Gastric Cancer Market: Snapshot
8.2 Middle East and Africa Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
8.3 Middle East and Africa Gastric Cancer Market: Key Factors
8.4 Middle East and Africa Gastric Cancer Market: Segment Analysis
8.5 Middle East and Africa Gastric Cancer Market Segmentation: By Indication
8.5.1 Middle East and Africa Gastric Cancer Market, By Indication Overview
8.5.2 Middle East and Africa Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
8.5.3 Middle East and Africa Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
8.6 Middle East and Africa Gastric Cancer Market Segmentation: By Therapy
8.6.1 Middle East and Africa Gastric Cancer Market, By Therapy Overview
8.6.2 Middle East and Africa Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
8.6.3 Middle East and Africa Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
8.6.3 Middle East and Africa Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
8.6.4 Middle East and Africa Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
8.7 Middle East and Africa Gastric Cancer Market Segmentation: By Drug Class
8.7.1 Middle East and Africa Gastric Cancer Market, By Drug Class Overview
8.7.2 Middle East and Africa Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
8.7.3 Middle East and Africa Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
8.7.4 Middle East and Africa Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
8.7.5 Middle East and Africa Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
8.2 Middle East and Africa Gastric Cancer Market: Market Size and CAGR, 2020-2030 (USD Billion & CAGR)
8.3 Middle East and Africa Gastric Cancer Market: Key Factors
8.4 Middle East and Africa Gastric Cancer Market: Segment Analysis
8.5 Middle East and Africa Gastric Cancer Market Segmentation: By Indication
8.5.1 Middle East and Africa Gastric Cancer Market, By Indication Overview
8.5.2 Middle East and Africa Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billion & CAGR)
8.5.3 Middle East and Africa Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billion & CAGR)
8.6 Middle East and Africa Gastric Cancer Market Segmentation: By Therapy
8.6.1 Middle East and Africa Gastric Cancer Market, By Therapy Overview
8.6.2 Middle East and Africa Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
8.6.3 Middle East and Africa Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billion & CAGR)
8.6.3 Middle East and Africa Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billion & CAGR)
8.6.4 Middle East and Africa Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billion & CAGR)
8.7 Middle East and Africa Gastric Cancer Market Segmentation: By Drug Class
8.7.1 Middle East and Africa Gastric Cancer Market, By Drug Class Overview
8.7.2 Middle East and Africa Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billion & CAGR)
8.7.3 Middle East and Africa Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
8.7.4 Middle East and Africa Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billion & CAGR)
8.7.5 Middle East and Africa Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billion & CAGR)
9. Market Dynamics
9.1 Impact assessment of Market Dynamics on Gastric Cancer Market
9.2 Drivers
9.3 Restraints
9.4 Trends
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Industry Ecosystem Analysis
10.1 Porter Analysis
11. Competitive Positioning
11.1 Companies’ Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of Gastric Cancer Market
11.4 Company Profiles
11.4.1 Novartis
11.4.2 Pfizer
11.4.3 GSK plc.
11.4.4 Bayer AG
11.4.5 Merck & Co., Inc.
11.4.6 F. Hoffmann-La Roche AG
11.4.7 Eli Lily & Co.
11.4.8 Celltrion Inc
11.4.9 Samsungbioepis Co,. Ltd
11.4.10 Bristol Myers Squibb
11.2 Market Position Matrix
11.3 Market Share Analysis of Gastric Cancer Market
11.4 Company Profiles
11.4.1 Novartis
11.4.2 Pfizer
11.4.3 GSK plc.
11.4.4 Bayer AG
11.4.5 Merck & Co., Inc.
11.4.6 F. Hoffmann-La Roche AG
11.4.7 Eli Lily & Co.
11.4.8 Celltrion Inc
11.4.9 Samsungbioepis Co,. Ltd
11.4.10 Bristol Myers Squibb
List of Figures
Figure 1: Five-year relative survival rates of type of gastric cancer
Figure 2: Prevalence of Gastric Cancer, 2021
Figure 3: Incidence of Gastric Cancer, 2021
Figure 4: Global Gastric Cancer Market Size, By Value, 2020-2023 (USD Billion)
Figure 5: Global Gastric Cancer Market Size, By Value, 2024-2030 (USD Billion)
Figure 6: Global Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 7: Market Attractiveness Analysis of Gastric Cancer Market, By Indication (2025-2030)
Figure 8: Global Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 9: Global Gastric Cancer Market Absolute Opportunity, By Gastric Cancer/Gastroesophageal Junction Cancer , 2020-2030 (USD Billion)
Figure 10: Global Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 11: Global Gastric Cancer Market Absolute Opportunity, By Gastrointestinal Stromal Tumors, 2020-2030 (USD Billion)
Figure 12: Market Attractiveness Analysis of Gastric Cancer Market, By Therapy (2025-2030)
Figure 13: Global Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 14: Global Gastric Cancer Market Absolute Opportunity, By Immunotherapy, 2020-2030 (USD Billion)
Figure 15: Global Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 16: Global Gastric Cancer Market Absolute Opportunity, By Chemotherapy, 2020-2030 (USD Billion)
Figure 17: Global Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 18: Global Gastric Cancer Market Absolute Opportunity, By Radiation Therapy and Surgery, 2020-2030 (USD Billion)
Figure 19: Global Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 20: Global Gastric Cancer Market Absolute Opportunity, By Target Therapies, 2020-2030 (USD Billion)
Figure 21: Market Attractiveness Analysis of Gastric Cancer Market, By Drug Class (2025-2030)
Figure 22: Global Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 23: Global Gastric Cancer Market Absolute Opportunity, By PD-1/PD-L1 Inhibitors, 2020-2030 (USD Billion)
Figure 24: Global Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 25: Global Gastric Cancer Market Absolute Opportunity, By HER2 Antagonists, 2020-2030 (USD Billion)
Figure 26: Global Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 27: Global Gastric Cancer Market Absolute Opportunity, By VEGFR2 Antagonists, 2020-2030 (USD Billion)
Figure 28: Global Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 29: Global Gastric Cancer Market Absolute Opportunity, By Other Drug Classes, 2020-2030 (USD Billion)
Figure 30: Americas Gastric Cancer Market Size, By Value, 2020H-2030F (USD Billion)
Figure 31: Americas Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 32: Americas Gastric Cancer Market, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 33: Americas Gastric Cancer Market, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 34: Americas Gastric Cancer Market, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 35: Americas Gastric Cancer Market, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 36: Americas Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 37: Americas Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 38: Americas Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 39: Americas Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 40: Americas Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 41: Americas Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 42: United States Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 43: United States Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 44: United States Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 45: United States Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 46: United States Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 47: Canada Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 48: Canada Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 49: Canada Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 50: Canada Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 51: Canada Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 52: Rest of Americas Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 53: Rest of Americas Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 54: Rest of Americas Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 55: Rest of Americas Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 56: Rest of Americas Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 57: Europe Gastric Cancer Market Size, By Value, 2020H-2030F (USD Billion)
Figure 58: Europe Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 59: Europe Gastric Cancer Market, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 60: Europe Gastric Cancer Market, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 61: Europe Gastric Cancer Market, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 62: Europe Gastric Cancer Market, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 63: Europe Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 64: Europe Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 65: Europe Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 66: Europe Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 67: Europe Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 68: Europe Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 69: Germany Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 70: Germany Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 71: Germany Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 72: Germany Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 73: Germany Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 74: United Kingdom Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 75: United Kingdom Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 76: United Kingdom Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 77: United Kingdom Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 78: United Kingdom Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 79: France Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 80: France Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 81: France Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 82: France Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 83: France Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 84: Italy Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 85: Italy Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 86: Italy Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 87: Italy Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 88: Italy Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 89: Spain Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 90: Spain Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 91: Spain Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 92: Spain Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 93: Spain Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 94: Rest of Europe Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 95: Rest of Europe Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 96: Rest of Europe Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 97: Rest of Europe Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 98: Rest of Europe Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 99: Asia Pacific Gastric Cancer Market Size, By Value, 2020H-2030F (USD Billion)
Figure 100: Asia Pacific Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 101: Asia Pacific Gastric Cancer Market, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 102: Asia Pacific Gastric Cancer Market, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 103: Asia Pacific Gastric Cancer Market, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 104: Asia Pacific Gastric Cancer Market, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 105: Asia Pacific Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 106: Asia Pacific Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 107: Asia Pacific Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 108: Asia Pacific Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 109: Asia Pacific Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 110: Asia Pacific Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 111: China Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 112: China Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 113: China Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 114: China Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 115: China Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 116: Japan Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 117: Japan Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 118: Japan Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 119: Japan Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 120: Japan Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 121: India Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 137: Middle East and Africa Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 138: Middle East and Africa Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 139: Middle East and Africa Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 140: Middle East and Africa Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 141: Middle East and Africa Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 142: Middle East and Africa Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 143: Market Share of Prominent Companies of Gastric Cancer Market, 2023 (%)
Figure 144: Novartis Revenues, 2021-2023 (USD Million)
Figure 145: Novartis Revenues, By Geographic Segments, 2023 (%)
Figure 146: Novartis Revenue , By Business Segments, 2023 (%)
Figure 147: Pfizer Revenues, 2020-2022 (USD Million)
Figure 148: Pfizer Revenues, By Business Segments, 2023 (%)
Figure 149: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
Figure 150: GSK PLC Revenue, 2020-2022 (USD Million)
Figure 151: GSK PLC Revenue , By Business Segments, 2022 (%)
Figure 152: GSK PLC Revenue, By Geography Segment, 2022 (%)
Figure 153: Bayer AG Revenues2021-2023(USD Million)
Figure 154: Bayer AG Revenues, By Geographic Segments, 2023 (%)
Figure 155: Bayer AG Revenues, By Business Segments, 2023 (%)
Figure 156: Merck & Co., Inc. Revenues, 2021-2023 (USD Million)
Figure 157: Merck & Co., Inc. Revenues, By Geographic Segments, 2023 (%)
Figure 158: Merck & Co., Inc. Revenue , By Business Segments, 2023 (%)
Figure 159: Roche Revenues, 2021-2023 (USD Million)
Figure 160: Roche Revenue , By Sales Division, 2023 (%)
Figure 161: Roche Revenue , By Geographical Segment, 2023 (%)
Figure 162: Eli Lily & Co. Revenues, 2021-2023 (USD Million)
Figure 163: Eli Lily & Co. Revenues, By Geographic Segments, 2023 (%)
Figure 164: Eli Lily & Co. Revenue , By Business Segments, 2023 (%)
Figure 165: Celltrion Inc Revenues, 2021-2023 (USD Billion)
Figure 166: Celltrion Inc Revenues, By Geographic Segments, 2023 (%)
Figure 167: Samsungbioepis Revenues, 2021-2023 (USD Billion)
Figure 168: Samsungbioepis Revenues, By Business Segments, 2023 (%)
Figure 169: Bristol Myers Squibb Revenues, 2021-2023 (USD Million)
Figure 170: Bristol Myers Squibb Revenues, By Geographic Segments, 2023 (%)
Figure 171: Bristol Myers Squibb Revenue , By Products, 2023 (%)
Figure 2: Prevalence of Gastric Cancer, 2021
Figure 3: Incidence of Gastric Cancer, 2021
Figure 4: Global Gastric Cancer Market Size, By Value, 2020-2023 (USD Billion)
Figure 5: Global Gastric Cancer Market Size, By Value, 2024-2030 (USD Billion)
Figure 6: Global Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 7: Market Attractiveness Analysis of Gastric Cancer Market, By Indication (2025-2030)
Figure 8: Global Gastric Cancer Market Size, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 9: Global Gastric Cancer Market Absolute Opportunity, By Gastric Cancer/Gastroesophageal Junction Cancer , 2020-2030 (USD Billion)
Figure 10: Global Gastric Cancer Market Size, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 11: Global Gastric Cancer Market Absolute Opportunity, By Gastrointestinal Stromal Tumors, 2020-2030 (USD Billion)
Figure 12: Market Attractiveness Analysis of Gastric Cancer Market, By Therapy (2025-2030)
Figure 13: Global Gastric Cancer Market Size, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 14: Global Gastric Cancer Market Absolute Opportunity, By Immunotherapy, 2020-2030 (USD Billion)
Figure 15: Global Gastric Cancer Market Size, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 16: Global Gastric Cancer Market Absolute Opportunity, By Chemotherapy, 2020-2030 (USD Billion)
Figure 17: Global Gastric Cancer Market Size, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 18: Global Gastric Cancer Market Absolute Opportunity, By Radiation Therapy and Surgery, 2020-2030 (USD Billion)
Figure 19: Global Gastric Cancer Market Size, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 20: Global Gastric Cancer Market Absolute Opportunity, By Target Therapies, 2020-2030 (USD Billion)
Figure 21: Market Attractiveness Analysis of Gastric Cancer Market, By Drug Class (2025-2030)
Figure 22: Global Gastric Cancer Market Size, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 23: Global Gastric Cancer Market Absolute Opportunity, By PD-1/PD-L1 Inhibitors, 2020-2030 (USD Billion)
Figure 24: Global Gastric Cancer Market Size, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 25: Global Gastric Cancer Market Absolute Opportunity, By HER2 Antagonists, 2020-2030 (USD Billion)
Figure 26: Global Gastric Cancer Market Size, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 27: Global Gastric Cancer Market Absolute Opportunity, By VEGFR2 Antagonists, 2020-2030 (USD Billion)
Figure 28: Global Gastric Cancer Market Size, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 29: Global Gastric Cancer Market Absolute Opportunity, By Other Drug Classes, 2020-2030 (USD Billion)
Figure 30: Americas Gastric Cancer Market Size, By Value, 2020H-2030F (USD Billion)
Figure 31: Americas Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 32: Americas Gastric Cancer Market, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 33: Americas Gastric Cancer Market, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 34: Americas Gastric Cancer Market, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 35: Americas Gastric Cancer Market, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 36: Americas Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 37: Americas Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 38: Americas Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 39: Americas Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 40: Americas Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 41: Americas Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 42: United States Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 43: United States Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 44: United States Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 45: United States Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 46: United States Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 47: Canada Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 48: Canada Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 49: Canada Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 50: Canada Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 51: Canada Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 52: Rest of Americas Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 53: Rest of Americas Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 54: Rest of Americas Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 55: Rest of Americas Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 56: Rest of Americas Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 57: Europe Gastric Cancer Market Size, By Value, 2020H-2030F (USD Billion)
Figure 58: Europe Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 59: Europe Gastric Cancer Market, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 60: Europe Gastric Cancer Market, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 61: Europe Gastric Cancer Market, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 62: Europe Gastric Cancer Market, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 63: Europe Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 64: Europe Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 65: Europe Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 66: Europe Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 67: Europe Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 68: Europe Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 69: Germany Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 70: Germany Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 71: Germany Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 72: Germany Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 73: Germany Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 74: United Kingdom Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 75: United Kingdom Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 76: United Kingdom Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 77: United Kingdom Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 78: United Kingdom Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 79: France Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 80: France Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 81: France Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 82: France Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 83: France Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 84: Italy Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 85: Italy Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 86: Italy Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 87: Italy Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 88: Italy Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 89: Spain Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 90: Spain Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 91: Spain Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 92: Spain Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 93: Spain Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 94: Rest of Europe Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 95: Rest of Europe Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 96: Rest of Europe Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 97: Rest of Europe Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 98: Rest of Europe Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 99: Asia Pacific Gastric Cancer Market Size, By Value, 2020H-2030F (USD Billion)
Figure 100: Asia Pacific Gastric Cancer Market Share, By Drug Class, 2023 (%)
Figure 101: Asia Pacific Gastric Cancer Market, By Gastric Cancer/Gastroesophageal Junction Cancer , By Value, 2020H-2030F (USD Billions & CAGR)
Figure 102: Asia Pacific Gastric Cancer Market, By Gastrointestinal Stromal Tumors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 103: Asia Pacific Gastric Cancer Market, By Immunotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 104: Asia Pacific Gastric Cancer Market, By Chemotherapy, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 105: Asia Pacific Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 106: Asia Pacific Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 107: Asia Pacific Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 108: Asia Pacific Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 109: Asia Pacific Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 110: Asia Pacific Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 111: China Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 112: China Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 113: China Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 114: China Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 115: China Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 116: Japan Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 117: Japan Gastric Cancer Market Value, By Therapy, 2023 (USD Billion)
Figure 118: Japan Gastric Cancer Market Share, By Indication, By Value, 2023 (%)
Figure 119: Japan Gastric Cancer Market Share, By Therapy, By Value, 2023 (%)
Figure 120: Japan Gastric Cancer Market Share, By Drug Class, By Value, 2023 (%)
Figure 121: India Gastric Cancer Market, By Value, 2020-2030 (USD Billions & CAGR)
Figure 137: Middle East and Africa Gastric Cancer Market, By Radiation Therapy and Surgery, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 138: Middle East and Africa Gastric Cancer Market, By Target Therapies, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 139: Middle East and Africa Gastric Cancer Market, By PD-1/PD-L1 Inhibitors, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 140: Middle East and Africa Gastric Cancer Market, By HER2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 141: Middle East and Africa Gastric Cancer Market, By VEGFR2 Antagonists, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 142: Middle East and Africa Gastric Cancer Market, By Other Drug Classes, By Value, 2020H-2030F (USD Billions & CAGR)
Figure 143: Market Share of Prominent Companies of Gastric Cancer Market, 2023 (%)
Figure 144: Novartis Revenues, 2021-2023 (USD Million)
Figure 145: Novartis Revenues, By Geographic Segments, 2023 (%)
Figure 146: Novartis Revenue , By Business Segments, 2023 (%)
Figure 147: Pfizer Revenues, 2020-2022 (USD Million)
Figure 148: Pfizer Revenues, By Business Segments, 2023 (%)
Figure 149: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
Figure 150: GSK PLC Revenue, 2020-2022 (USD Million)
Figure 151: GSK PLC Revenue , By Business Segments, 2022 (%)
Figure 152: GSK PLC Revenue, By Geography Segment, 2022 (%)
Figure 153: Bayer AG Revenues2021-2023(USD Million)
Figure 154: Bayer AG Revenues, By Geographic Segments, 2023 (%)
Figure 155: Bayer AG Revenues, By Business Segments, 2023 (%)
Figure 156: Merck & Co., Inc. Revenues, 2021-2023 (USD Million)
Figure 157: Merck & Co., Inc. Revenues, By Geographic Segments, 2023 (%)
Figure 158: Merck & Co., Inc. Revenue , By Business Segments, 2023 (%)
Figure 159: Roche Revenues, 2021-2023 (USD Million)
Figure 160: Roche Revenue , By Sales Division, 2023 (%)
Figure 161: Roche Revenue , By Geographical Segment, 2023 (%)
Figure 162: Eli Lily & Co. Revenues, 2021-2023 (USD Million)
Figure 163: Eli Lily & Co. Revenues, By Geographic Segments, 2023 (%)
Figure 164: Eli Lily & Co. Revenue , By Business Segments, 2023 (%)
Figure 165: Celltrion Inc Revenues, 2021-2023 (USD Billion)
Figure 166: Celltrion Inc Revenues, By Geographic Segments, 2023 (%)
Figure 167: Samsungbioepis Revenues, 2021-2023 (USD Billion)
Figure 168: Samsungbioepis Revenues, By Business Segments, 2023 (%)
Figure 169: Bristol Myers Squibb Revenues, 2021-2023 (USD Million)
Figure 170: Bristol Myers Squibb Revenues, By Geographic Segments, 2023 (%)
Figure 171: Bristol Myers Squibb Revenue , By Products, 2023 (%)
List of Tables
Table A1: Global Impact of Macro Economic Factors, By Region
Table A2: United States Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A3: United States Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A4: United States Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A5: United States Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A6: United States Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A7: United States Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A8: Canada Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A9: Canada Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A10: Canada Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A11: Canada Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A12: Canada Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A13: Canada Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A14: Rest of Americas Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A15: Rest of Americas Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A16: Rest of Americas Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A17: Rest of Americas Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A18: Rest of Americas Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A19: Rest of Americas Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A20: Germany Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A21: Germany Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A22: Germany Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A23: Germany Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A24: Germany Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A25: Germany Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A26: United Kingdom Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A27: United Kingdom Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A28: United Kingdom Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A29: United Kingdom Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A30: United Kingdom Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A31: United Kingdom Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A32: France Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A33: France Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A34: France Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A35: France Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A36: France Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A37: France Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A38: Italy Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A39: Italy Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A40: Italy Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A41: Italy Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A42: Italy Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A43: Italy Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A44: Spain Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A45: Spain Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A46: Spain Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A47: Spain Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A48: Spain Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A49: Spain Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A50: Rest of Europe Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A51: Rest of Europe Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A52: Rest of Europe Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A53: Rest of Europe Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A54: Rest of Europe Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A55: Rest of Europe Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A56: China Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A57: China Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A58: China Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A59: China Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A60: China Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A61: China Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A62: Japan Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A63: Japan Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A64: Japan Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A65: Japan Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A66: Japan Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A67: Japan Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A68: India Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A69: India Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A70: India Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A71: India Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A72: India Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A73: India Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A74: Rest of Asia Pacific Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A75: Rest of Asia Pacific Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A76: Rest of Asia Pacific Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A77: Rest of Asia Pacific Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A78: Rest of Asia Pacific Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A79: Rest of Asia Pacific Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A80: Novartis Key Financials, 2021-2023
Table A81: Pfizer Key Financials, 2021-2023
Table A82: GSK PLC Key Company Financials, 2020-2022
Table A83: Bayer AG Key Financials, 2021-2023
Table A84: Merck & Co., Inc. Key Financials, 2021-2023
Table A85: Roche Key Financials, 2021-2023
Table A86: Eli Lily & Co. Key Financials, 2021-2023
Table A87: Celltrion Inc Key Financials, 2021-2023
Table A88: Bristol Myers Squibb Key Financials, 2021-2023
Table A2: United States Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A3: United States Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A4: United States Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A5: United States Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A6: United States Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A7: United States Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A8: Canada Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A9: Canada Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A10: Canada Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A11: Canada Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A12: Canada Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A13: Canada Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A14: Rest of Americas Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A15: Rest of Americas Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A16: Rest of Americas Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A17: Rest of Americas Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A18: Rest of Americas Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A19: Rest of Americas Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A20: Germany Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A21: Germany Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A22: Germany Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A23: Germany Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A24: Germany Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A25: Germany Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A26: United Kingdom Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A27: United Kingdom Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A28: United Kingdom Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A29: United Kingdom Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A30: United Kingdom Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A31: United Kingdom Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A32: France Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A33: France Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A34: France Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A35: France Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A36: France Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A37: France Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A38: Italy Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A39: Italy Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A40: Italy Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A41: Italy Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A42: Italy Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A43: Italy Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A44: Spain Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A45: Spain Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A46: Spain Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A47: Spain Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A48: Spain Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A49: Spain Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A50: Rest of Europe Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A51: Rest of Europe Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A52: Rest of Europe Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A53: Rest of Europe Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A54: Rest of Europe Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A55: Rest of Europe Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A56: China Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A57: China Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A58: China Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A59: China Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A60: China Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A61: China Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A62: Japan Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A63: Japan Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A64: Japan Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A65: Japan Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A66: Japan Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A67: Japan Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A68: India Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A69: India Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A70: India Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A71: India Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A72: India Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A73: India Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A74: Rest of Asia Pacific Gastric Cancer Market, By Indication, By Value, 2020-2023 (USD Billion)
Table A75: Rest of Asia Pacific Gastric Cancer Market, By Indication, By Value, 2025-2030 (USD Billion)
Table A76: Rest of Asia Pacific Gastric Cancer Market, By Therapy, By Value, 2020-2023 (USD Billion)
Table A77: Rest of Asia Pacific Gastric Cancer Market, By Therapy, By Value, 2025-2030 (USD Billion)
Table A78: Rest of Asia Pacific Gastric Cancer Market, By Drug Class, By Value, 2020-2023 (USD Billion)
Table A79: Rest of Asia Pacific Gastric Cancer Market, By Drug Class, By Value, 2025-2030 (USD Billion)
Table A80: Novartis Key Financials, 2021-2023
Table A81: Pfizer Key Financials, 2021-2023
Table A82: GSK PLC Key Company Financials, 2020-2022
Table A83: Bayer AG Key Financials, 2021-2023
Table A84: Merck & Co., Inc. Key Financials, 2021-2023
Table A85: Roche Key Financials, 2021-2023
Table A86: Eli Lily & Co. Key Financials, 2021-2023
Table A87: Celltrion Inc Key Financials, 2021-2023
Table A88: Bristol Myers Squibb Key Financials, 2021-2023
Companies Mentioned
- Novartis
- Pfizer
- GSK plc.
- Bayer AG
- Merck & Co., Inc.
- F. Hoffmann-La Roche AG
- Eli Lily & Co.
- Celltrion Inc
- Samsungbioepis Co,. Ltd
- Bristol Myers Squibb
